Joint Ventures	12 Months Ended
Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Joint Ventures	Joint VenturesThe Company has two joint ventures with China National Tobacco Corporation ("CNTC"). CNTC is the principal operating company under China’s State Tobacco Monopoly Administration. CNTC and the Company’s subsidiary, Schweitzer-Mauduit International China, Limited ("SM-China"), each own 50% of each of the joint ventures. The paper joint venture China Tobacco Mauduit (Jiangmen) Paper Industry Co. LTD, produces tobacco-related papers in China. The second joint venture China Tobacco Schweitzer (Yunnan) Reconstituted Tobacco Co. LTD, produces reconstituted tobacco leaf products. The joint ventures pay each, the Company and CNTC, sales-based royalties and management fees, of which we recognized $2.6 million, $2.7 million, and $2.0 million during the years ended December 31, 2022, 2021 and 2020, respectively, in Other income (expense), net in the Consolidated Statements of Income (Loss).The Company uses the equity method to account for its ownership interest in both joint ventures. At December 31, 2022 and 2021, the Company’s equity investment in the joint ventures was $59.1 million and $64.6 million, respectively. The Company’s share of the net income was included in Income from equity affiliates, net of income taxes in the Consolidated Statements of Income (Loss). We evaluate our equity method investments for impairment when events or changes in circumstances indicate, in our judgment, that the carrying value of such investment may have experienced an other than temporary decline in value. When evidence of loss in value has occurred, we compare the estimated fair value of the investment to the carrying value of the investment to determine whether impairment has occurred. We assess the fair value of our equity method investment using commonly accepted techniques, and may use more than one method, including, but not limited to, internally developed analysis and analysis of external data. If the estimated fair value is less than the carrying value and we consider the decline in value to be other than temporary, the excess of the carrying value over the estimated fair value is recognized in the consolidated financial statements as an impairment.

Joint Ventures

12 Months Ended

Dec. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Joint VenturesThe Company has two joint ventures with China National Tobacco Corporation ("CNTC"). CNTC is the principal operating company under China’s State Tobacco Monopoly Administration. CNTC and the Company’s subsidiary, Schweitzer-Mauduit International China, Limited ("SM-China"), each own 50% of each of the joint ventures. The paper joint venture China Tobacco Mauduit (Jiangmen) Paper Industry Co. LTD, produces tobacco-related papers in China. The second joint venture China Tobacco Schweitzer (Yunnan) Reconstituted Tobacco Co. LTD, produces reconstituted tobacco leaf products. The joint ventures pay each, the Company and CNTC, sales-based royalties and management fees, of which we recognized $2.6 million, $2.7 million, and $2.0 million during the years ended December 31, 2022, 2021 and 2020, respectively, in Other income (expense), net in the Consolidated Statements of Income (Loss).The Company uses the equity method to account for its ownership interest in both joint ventures. At December 31, 2022 and 2021, the Company’s equity investment in the joint ventures was $59.1 million and $64.6 million, respectively. The Company’s share of the net income was included in Income from equity affiliates, net of income taxes in the Consolidated Statements of Income (Loss). We evaluate our equity method investments for impairment when events or changes in circumstances indicate, in our judgment, that the carrying value of such investment may have experienced an other than temporary decline in value. When evidence of loss in value has occurred, we compare the estimated fair value of the investment to the carrying value of the investment to determine whether impairment has occurred. We assess the fair value of our equity method investment using commonly accepted techniques, and may use more than one method, including, but not limited to, internally developed analysis and analysis of external data. If the estimated fair value is less than the carrying value and we consider the decline in value to be other than temporary, the excess of the carrying value over the estimated fair value is recognized in the consolidated financial statements as an impairment.